Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial registry entry evaluating the combination of glumetinib and albumin-bound docetaxel versus docetaxel alone for MET-overexpressed non-sm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Docetaxel (Albumin Bound) (docetaxel)
• Glumetinib

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression | Phase 2 | Status: NOT_YET_RECRUITING